CLAIMS:

1. Use of a nitric oxide releasing solution (NORS) in the manufacture of a medicament for treating a condition responsive to nitric oxide (NO) treatment in a subject comprising:

the subject is to be administered a volume of a nitric oxide releasing solution (NORS) that provides a therapeutically effective amount of NO to an administration situs of the subject for a treatment duration, wherein the NORS includes a nitric oxide releasing compound and an acidifying agent, wherein when measured by releasing NO from the NORS for a period of 30 minutes into a flow of substantially inert carrier gas at a flow rate of 1 liter per minute and a pressure of 1 atmosphere, coupled to a chemiluminescence detector, said NORS releases NO in an amount of from about 1 ppm*min/mL to about 500 ppm*min/mL based on 1 mL of the NORS.

2. The use of claim 1, wherein the NORS releases the NO in an amount of from about 1 ppm*min to about 60 ppm*min per mL of the NORS.

3. The use of claim 1, wherein the volume of the NORS is from about 0.1 mL to about 10,000 mL.

4. The use of claim 1, wherein the total amount of NO released by the volume of NORS is to be administered is from about 6 ppm*min to about 75,000 ppm*min.

5. The use of claim 1, wherein the condition is a wound, a skin infection, a fungal infection, a respiratory infection, a bacterial infection, or a viral infection.

6. The use of claim 1, wherein the condition is athlete’s foot and the administration situs is a foot of the subject, and wherein the NORS releases NO in an amount from about 5 ppm*min/mL to about 15 ppm*min/mL based on 1 mL of the NORS.

7. The use of claim 6, wherein the total amount of NO released by the volume of NORS is to be administered is from about 25,000 ppm*min to about 75,000 ppm*min.

8. The use of claim 6, wherein the volume of NORS is to be administered is from about 500 mL to about 10,000 mL.

9. The use of claim 6, wherein the volume of NORS is to be administered releases a peak NO concentration of from about 5,000 ppm to about 20,000 ppm.

10. The use of claim 1, wherein the condition is onychomycosis and the administration situs is a nail of the subject, and wherein the NORS releases NO in an amount from about 25 ppm*min/mL to about 75 ppm*min/mL based on 1 mL of the NORS.

11. The use of claim 10, wherein the total amount of NO released by the volume of NORS is to be administered is from about 25 ppm*min to about 75 ppm*min.

12. The use of claim 10, wherein the volume of NORS is to be administered is from about 0.1 mL to about 2 mL.

13. The use of claim 10, wherein the volume of NORS is to be administered releases a peak NO concentration of from about 5 ppm to about 30 ppm.

14. The use of claim 1, wherein the condition is influenza and the administration situs is a nasal cavity of the subject, and wherein the NORS releases the NO in an amount from about 2 ppm*min/mL to about 30 ppm*min/mL based on 1 mL of the NORS.

15. The use of claim 14, wherein the total amount of NO released by the volume of NORS is to be administered is from about 1 ppm*min to about 15 ppm*min.

16. The use of claim 14, wherein the volume of NORS is to be administered is from about 0.1 mL to about 2 mL.

17. The use of claim 14, wherein the volume of NORS is to be administered releases a peak NO concentration of from about 0.5 ppm to about 5 ppm.

18. The use of claim 1, wherein the condition is a respiratory viral infection and the administration situs is a nasal cavity or lungs of the subject, and wherein the

NORS releases NO in an amount from about 2 ppm*min/mL to about 30 ppm*min/mL based on 1 mL of the NORS.

19. The use of claim 18, wherein the total amount of NO released by the volume of NORS is to be administered is from about 1 ppm*min to about 15 ppm*min.

20. The use of claim 18, wherein the volume of NORS is to be administered is from about 0.1 mL to about 2 mL.

21. The use of claim 18, wherein the volume of NORS is to be administered releases a peak NO concentration of from about 0.5 ppm to about 5 ppm.

22. The use of claim 1, wherein the condition is sinusitis and the administration situs is a sinus cavity of the subject, and wherein the NORS releases NO in an amount from about 0.5 ppm*min/mL to about 30 ppm*min/mL based on 1 mL of the NORS.

23. The use of claim 22, wherein the total amount of NO released by the volume of NORS is to be administered is from about 100 ppm*min to about 5,000 ppm*min.

24. The use of claim 22, wherein the volume of NORS is to be administered is from about 150 mL to about 300 mL.

25. The use of claim 22, wherein the volume of NORS is to be administered releases a peak NO concentration of from about 50 ppm to about 1,500 ppm.

26. The use of claim 1, wherein the condition is a throat infection and the administration situs is the throat of the subject, and wherein the NORS releases NO in an amount from about 10 ppm*min/mL to about 40 ppm*min/mL based on 1 mL of the NORS.

27. The use of claim 26, wherein the total amount of NO released by the volume of NORS is to be administered is from about 200 ppm*min to about 800 ppm*min.

28. The use of claim 26, wherein the volume of NORS is to be administered is from about 5 mL to about 40 mL.

29. The use of claim 26, wherein the volume of NORS is to be administered releases a peak NO concentration of from about 100 ppm to about 200 ppm.

30. The use of claim 1, wherein the condition is acne and the administration situs is a skin area of the subject, and wherein the NORS releases NO in an amount from about 5 ppm*min/mL to about 30 ppm*min/mL based on 1 mL of the NORS.

31. The use of claim 30, wherein the total amount of NO released by the volume of NORS is to be administered is from about 10 ppm*min to about 60 ppm*min.

32. The use of claim 30, wherein the volume of NORS is to be administered is from about 1 mL to about 5 mL.

33. The use of claim 30, wherein the volume of NORS is to be administered releases a peak NO concentration of from about 5 ppm to about 20 ppm.

34. The use of claim 1, wherein the condition is a diabetic foot ulcer and the administration situs is a foot of the subject, and wherein the NORS releases NO in an amount from about 5 ppm*min/mL to about 80 ppm*min/mL based on 1 mL of the NORS.

35. The use of claim 34, wherein the total amount of NO released by the volume of NORS is to be administered is from about 100 ppm*min to about 75,000 ppm*min.

36. The use of claim 34, wherein the volume of NORS is to be administered is from about 5 mL to about 10,000 mL.

37. The use of claim 34, wherein the volume of NORS is to be administered releases a peak NO concentration of from about 50 ppm to about 20,000 ppm.

38. The use of claim 1, wherein the condition is a warts and the administration situs is a skin area of the subject, and wherein the NORS releases NO in an amount from about 10 ppm*min/mL to about 60 ppm*min/mL based on 1 mL of the NORS.

39. The use of claim 38, wherein the total amount of NO released by the volume of NORS is to be administered is from about 20 ppm*min to about 400 ppm*min.

40. The use of claim 38, wherein the volume of NORS is to be administered is from about 0.5 mL to about 10 mL.

41. The use of claim 38, wherein the volume of NORS is to be administered releases a peak NO concentration of from about 1 ppm to about 60 ppm.

42. The use of claim 1, wherein the nitric oxide releasing compound comprises sodium nitrite, potassium nitrite, barium nitrite, calcium nitrite, nitrite orotate, amyl nitrite, magnesium nitrite, silver nitrite, copper nitrite, or a combination thereof.

43. The use of claim 1, wherein the acidifying agent comprises ascorbic acid, ascorbyl palmitate, salicylic acid, malic acid, lactic acid, citric acid, formic acid, benzoic acid, tartaric acid, hydrochloric acid, sulfuric acid, phosphoric acid, or a combination thereof.

44. The use of claim 1, wherein the NORS provides an extended release of NO.

45. The use of claim 1, wherein the NORS is to be administered as an intranasal spray, an open vessel bath for soaking, a liquid sinus wash, a liquid gargling solution, a respiratory inhaler, an aerosol, a gel, a foam, an emulsion, a liquid solution, a cream, or a combination thereof.

46. The use of claim 1, wherein the NORS comprises a pharmaceutically acceptable carrier.

47. The use of claim 46, wherein the pharmaceutically acceptable carrier comprises water, saline, hydroxyethyl cellulose, xanthan gum, or a combination thereof.

48. A composition, comprising:

a combination of a nitric oxide releasing compound, an acidifying agent, and a carrier in amounts that release from about 1 ppm*min/mL to about 500 ppm*min/mL nitric oxide (NO) based on 1 mL of the composition when measured by releasing NO from the composition for a period of 30 minutes into a flow of substantially inert carrier gas at a flow rate of 1 liter per minute and a pressure of

1 atmosphere, coupled to a chemiluminescence detector.

49. The composition of claim 48, wherein the pharmaceutically acceptable carrier comprises water, saline, hydroxyethyl cellulose, xanthan gum, or a combination thereof.

50. The composition of claim 48, wherein the composition is formulated to be administered as an intranasal spray, an open vessel bath for soaking, a liquid sinus wash, a liquid gargling solution, a respiratory inhaler, an aerosol, a gel, a foam, an emulsion, a liquid solution, a cream, or a combination thereof.

51. The composition of claim 65, wherein the amount of NO released is from about 1 ppm*min/mL to about 500 ppm*min/mL.

52. The composition of claim 48, wherein the nitric oxide releasing compound comprises sodium nitrite, potassium nitrite, barium nitrite, calcium nitrite, nitrite orotate, amyl nitrite, magnesium nitrite, silver nitrite, copper nitrite, or a combination thereof.

53. The composition of claim 48, wherein the acidifying agent comprises ascorbic acid, ascorbyl palmitate, salicylic acid, malic acid, lactic acid, citric acid, formic acid, benzoic acid, tartaric acid, hydrochloric acid, sulfuric acid, phosphoric acid, or a combination thereof.

54. The composition of claim 48, wherein the composition provides an extended release of NO.

55. The composition of claim 48, wherein the composition is an intranasal spray, an open vessel bath for soaking, a liquid sinus wash, a liquid gargling solution, a respiratory inhaler, an aerosol, a gel, a foam, an emulsion, a liquid solution, a cream, or a combination thereof.